List view / Grid view
22 October 2015 | By Victoria White
Genvoya was found to be statistically non-inferior to Stribild based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL...
22 October 2015 | By Victoria White
Trial startup activities are underway and MacroGenics expects to begin enrolling patients by the first quarter of 2016...
Life scientists who work with DNA, RNA and proteins can make educated decisions about sample suitability in experiments using a standalone, microvolume spectrophotometer for accurate quantitation and purity measurements to ensure downstream application success.
22 October 2015 | By Victoria White
GS-5734 was discovered as part of Gilead’s programme to screen compounds in its libraries for activity against a range of potential emerging viruses, including Ebola...
22 October 2015 | By Victoria White
The CPhI Pharma Awards recognise life sciences firms that turn inspiration into innovation, and celebrate thinkers and creators that are breaking new ground in formulation, process development, packaging, technology, and more...
22 October 2015 | By Victoria White
Under the terms of the expanded agreement, AstraZeneca and Lilly will evaluate the safety and efficacy of a range of additional combinations across the companies’ portfolios...
21 October 2015 | By Victoria White
Research has found that women whose breast cancer had begun to spread and who tested positive in the αB-crystallin test were three times more likely to have disease that spread to the brain...
21 October 2015 | By Victoria White
The new draft guidance is different to the original 2007 guidance because it reflects the fact that current clinical practice has a greater emphasis on managing CVD risk rather than meeting target cholesterol levels...
21 October 2015 | By Victoria White
Until this orphan drug approval, no specific coagulation factor replacement therapy was available in the US for patients with hereditary Factor X deficiency...
21 October 2015 | By Victoria White
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis did not achieve its primary and secondary endpoints...
21 October 2015 | By Victoria White
The results come from two head-to-head studies directly comparing the efficacy and safety of umeclidinium to two available bronchodilator treatments...
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
20 October 2015 | By Victoria White
The 2015 UNESCO-Merck Africa Research Summit will focus on the role of building capacities in the life sciences to address challenges of infectious diseases, most notably the Ebola crises...
20 October 2015 | By Victoria White
Commercial production will begin at the new state-of-the-art site early next year and will focus on final-stage manufacturing, packaging and quality control...
20 October 2015 | By Victoria White
The treatment market for multiple myeloma across China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021...
